06 Jun

EGFR MUTATION DETECTION (EXONS 18-21)

vincentochiengde

Category

Molecular genetic pathology & cytogenetics

Sub Category

Oncology (Solid Tumors)

Synonym/Aliases

Epidermal Growth Factor Receptor (Egfr) Mutation Analysis.

Abbreviations

- N/A

Type

Individual Test

Results

RESULTS READY AFTER 21 WORKING DAYS

Method

REAL TIME PCR

Temp

ROOM TEMPERATURE; REFRIGERATED IS ALSO ACCEPTABLE.

Setup

BATCHED

Components Parameters

- N/A

PRE-ANALYTIC CONSIDERATIONS

Test Ordering Instructions

FILL OUT TEST REQUEST FORM FULLY & LEGIBLY. CLINICAL HISTORY, HISTOLOGY (H&E) REPORT ARE MANDATORY.

Patient preparation

-N/A

Sample type

TUMOR POSITIVE FORMALIN-FIXED, PARAFFIN-EMBEDDED (FFPE) BLOCK.

Container/ preservative

FORMALIN FIXED, PARAFFIN EMBEDDED BLOCKS.

Sample volume

SUFFICIENT RESIDUAL TISSUE/ TUMOR MUST BE AVAILABLE ON THE BLOCK

Rejection criteria

LABELING ISSUE (UNLABELED/ MISLABELED); MISSING REQUEST FORM; MISMATCH BETWEEN REQUEST FORM & SAMPLE DETAILS; WRONG SAMPLE TYPE OR FIXATIVE; INSUFFICIENT/ DEPLETED SAMPLE.

Other Instructions

IF TISSUE IS PROVIDED, THEN TISSUE PROCESSING CHARGES WILL BE APPLICABLE

Reference intervals

INTERPRETIVE DATA IS PROVIDED ON THE REPORT.

Clinical Utility

EGFR POSITIVE PATIENTS WITH LUNG CANCER BENEFIT FROM EFGR TARGETED THERAPY E.G. GEFITINIB (IRESSA), ERLOTINIB (TARCEVA).

Test Limitations/ Confounders

- N/A
05 Jun

DNA MATERNITY TESTING

vincentochiengde

Category

Molecular genetic pathology & cytogenetics

Sub Category

Cytogenetics

Synonym/Aliases

- N/A

Abbreviations

- N/A

Type

profile/ panel (bundled tests)

Results

RESULTS READY AFTER 14 DAYS / 2 WEEKS.

Method

PCR

Temp

REFRIGERATE EDTA WHOLE BLOOD. DBS CAARDS AT ROOM TEMPERATURE.

Setup

BATCHED

Components Parameters

multiple genetic markers

PRE-ANALYTIC CONSIDERATIONS

Test Ordering Instructions

FILL OUT TEST REQUEST FORM FULLY & LEGIBLY. NUMBER OF CHILDREN BEING ASSESSED MUST BE SPECIFIED. PRICE DEPENDS ON NUMBER OF CHILDREN WHOSE PARENTAGE IS BEING ASSESSED. OFFERED TO WALK-IN CLIENTS & FOR PERSONAL KNOWLEDGE (NON-LEGAL) ONLY.

Patient preparation

FULLY FILLED CONSENT FORM. PASSPORT PHOTOS OF ALL PARTIES INVOLVED. COPY OF NATIONAL ID/ PASSPORT OF ALL ADULTS, ORIGINAL & COPY OF BIRTH CERTIFICATE FOR EACH CHILD <18 YEARS.

Sample type

EDTA WHOLE BLOOD

Container/ preservative

EDTA (PURPLE TOP) VACUTAINER OR BLOOD SPOT ON A DRIED BLOOD SPOT (DBS)/ GUTHRIE CARD.

Sample volume

3 ML PER PERSON.

Rejection criteria

LABELING ISSUE (UNLABELED/ MISLABELED); MISSING REQUEST FORM; MISMATCH BETWEEN REQUEST FORM & SAMPLE DETAILS; MISSING AGE/ GENDER; WRONG SAMPLE TYPE; INSUFFICIENT SAMPLE; MISSING DOCUMENTATION.

Other Instructions

- N/A

Reference intervals

MATERNITY NOT EXCLUDED (MEANS THAT RESULTS ARE CONSISTENT WITH THE BIOLOGICAL MOTHER BEING THE ALLEGED BIOLOICAL PARENT). INTERPRETIVE DATA IS PROVIDED ON THE REPORT.

Clinical Utility

CONFIRM OR REFUTE MATERNITY OF AN ALLEGED MOTHER.

Test Limitations/ Confounders

EQUIVOCAL RESULTS MAY SOMETIMES BE OBTAINED WHEN FATHER'S SAMPLE IS NOT AVAILABLE. CANNOT DISTINGUISH BETWEEN ALLEGED BIOLOGICAL MOTHERS WHO ARE IDENTICAL TWINS.
05 Jun

DNA PATERNITY TESTING

vincentochiengde

Category

Molecular genetic pathology & cytogenetics

Sub Category

Cytogenetics

Synonym/Aliases

- N/A

Abbreviations

- N/A

Type

profile/ panel (bundled tests)

Results

RESULTS READY AFTER 14 DAYS/ 2 WEEKS.

Method

PCR

Temp

REFRIGERATE.

Setup

BATCHED

Components Parameters

multiple genetic markers

PRE-ANALYTIC CONSIDERATIONS

Test Ordering Instructions

FILL OUT TEST REQUEST FORM FULLY & LEGIBLY. NUMBER OF CHILDREN BEING ASSESSED MUST BE SPECIFIED. PRICE DEPENDS ON NUMBER OF CHILDREN WHOSE PARENTAGE IS BEING ASSESSED. OFFERED TO WALK-IN CLIENTS & FOR PERSONAL KNOWLEDGE (NON-LEGAL) ONLY.

Patient preparation

FULLY FILLED CONSENT FORM. PASSPORT PHOTOS OF ALL PARTIES INVOLVED. COPY OF NATIONAL ID/ PASSPORT OF ALL ADULTS, ORIGINAL & COPY OF BIRTH CERTIFICATE FOR EACH CHILD <18 YEARS.

Sample type

EDTA WHOLE BLOOD

Container/ preservative

EDTA (PURPLE TOP) VACUTAINER OR BLOOD SPOT ON A GUTHRIE CARD.

Sample volume

3 ML PER PERSON.

Rejection criteria

LABELING ISSUE (UNLABELED/ MISLABELED); MISSING REQUEST FORM; MISMATCH BETWEEN REQUEST FORM & SAMPLE DETAILS; MISSING AGE/ GENDER; WRONG SAMPLE TYPE; INSUFFICIENT SAMPLE; MISSING DOCUMENTATION.

Other Instructions

MOTHER'S CONSENT IS MANDATORY WHEN FATHER'S NAME IS NOT LISTED ON THE BIRTH CERTFICATE.

Reference intervals

PATERNITY NOT EXCLUDED (MEANS THAT RESULTS ARE CONSISTENT WITH THE BIOLOGICAL FATHER BEING THE ALLEGED BIOLOICAL PARENT). INTERPRETIVE DATA IS PROVIDED ON THE REPORT.

Clinical Utility

CONFIRM OR REFUTE PATERNITY OF AN ALLEGED FATHER.

Test Limitations/ Confounders

EQUIVOCAL RESULTS MAY SOMETIMES BE OBTAINED WHEN MOTHER'S SAMPLE IS NOT AVAILABLE (MOTHERLESS PATERNITY TESTING IS DISCOURAGED). CANNOT DISTINGUISH BETWEEN ALLEGED BIOLOGICAL FATHERS WHO ARE IDENTICAL TWINS.
05 Jun

CHROMOSOMAL MICROARRAY, CONGENITAL, BLOOD

vincentochiengde

Category

Molecular genetic pathology & cytogenetics

Sub Category

Cytogenetics

Synonym/Aliases

Congenital Snp Microarray; Postnatal Array Cgh; Congenital Array; Array Chrome

Abbreviations

ACGH; CMA

Type

INDIVIDUAL TEST

Results

RESULTS READY AFTER 18-21 DAYS

Method

CYTOGENOMIC MICROARRAY (CMA) USING BLOOD; CYTOGENOMIC SINGLE NUCLEOTIDE POLYMORPHISM (SNP) MICROARRAY.

Temp

REFRIGERATE; TIME SENSITIVE THEREFORE PROMPTLY NOTIFY & DELIVER TO THE LAB.

Setup

BATCHED

Components Parameters

N/A

PRE-ANALYTIC CONSIDERATIONS

Test Ordering Instructions

FILL OUT TEST REQUEST FORM FULLY & LEGIBLY. PROVIDE CLINICAL HISTORY

Patient preparation

N/A

Sample type

EDTA WHOLE BLOOD

Container/ preservative

EDTA (PURPLE TOP) VACUTAINER

Sample volume

3 ML (CHILDREN AT LEAST 1-2 ML).

Rejection criteria

LABELING ISSUE (UNLABELED/ MISLABELED); MISSING REQUEST FORM; MISMATCH BETWEEN REQUEST FORM & SAMPLE DETAILS; MISSING AGE/ GENDER; WRONG SAMPLE TYPE; INSUFFICIENT SAMPLE; HEMOLYZED SAMPLE, CLOTTED SAMPLE

Other Instructions

- N/A

Reference intervals

INTERPRETIVE DATA IS PROVIDED ON THE REPORT.

Clinical Utility

PRIMARILY USED FOR EVALUATION OF PEDIATRIC PATIENTS WITH DYSMORPHIC FEATURES, CONGENITAL ABNORMALITIES, AUTISM, INTELLECTUAL & LEARNING DISABILITIES, DEVELOPMENTAL DELAYS ETC. DIAGNOSIS OF CONGENITAL DISORDERS ARISING FROM GENOMIC COPY NUMBER VARIATIONS E.G. ANEUPLOIDIES (E.G. TRISOMIES, TURNER SYNDROME, KLINEFELTER SYNDROME), MOSAICISM >20%, MICRODELETIONS & MICRODUPLICATIONS WITHIN THE ASSAY'S RESOLUTION.

Test Limitations/ Confounders

CANNOT DETECT BALANCED CHROMOSOMAL REARRANGEMENTS, SINGLE GENE DISORDERS, MOSAICISM <20% ETC. HIGHER RISK OF UNCERTAIN & INCIDENTAL FINDINGS THAN KARYOTYPING.
05 Jun

CHROMOSOMAL MICROARRAY, PRODUCTS OF CONCEPTION (POC)/ STILLBIRTH

vincentochiengde

Category

Molecular genetic pathology & cytogenetics

Sub Category

Cytogenetics

Synonym/Aliases

SNP MICROARRAY; ARRAY CGH; ARRAY FETO

Abbreviations

poc acgh; poc cma

Type

Individual Test

Results

RESULTS READY AFTER 18-21 DAYS

Method

CYTOGENOMIC MICROARRAY (CMA) USING POCs; CYTOGENOMIC SINGLE NUCLEOTIDE POLYMORPHISM (SNP) MICROARRAY.

Temp

REFRIGERATE; TIME SENSITIVE THREFORE NOTIFY LAB PRIOR TO COLLECTION & PROMPTLY DELIVER SAMPLE TO THE LAB.

Setup

BATCHED

Components Parameters

N/A

PRE-ANALYTIC CONSIDERATIONS

Test Ordering Instructions

FILL OUT TEST REQUEST FORM FULLY & LEGIBLY. PROVIDE CLINICAL HISTORY

Patient preparation

N/A

Sample type

VIABLE FETAL TISSUE/ PRODUCTS OF CONCEPTION (POCs) IN TISSUE CULTURE MEDIA (OR RPMI/ HANK'S/ RINGER'S LACTATE/ NORMAL SALINE TO WHICH 2-3 DROPS OF GENTAMICIN HAVE BEEN ADDED). FIRST TRIMESTER LOSS: POCs IN CULTURE MEDIA OR NORMAL SALINE WITH ANTIBIOTICS. SECOND TRIMESTER AND BEYOND: DUAL SPECIMENS PREFERRED I.E. 1) PLACENTAL BIOPSY FROM FETAL SIDE WITHIN 1 INCH OF THE PLACENTAL INSERTION SITE PLUS 2) FETAL TISSUE (E.G. MUSCLE BIOPSY FROM MEDIAL ASPECT OF THE THIGH OR FETAL TOE).

Container/ preservative

TISSUE BIOPSY IN STERILE CONTAINER CONTAINING TISSUE CULTURE MEDIUM (OR RPMI/ HANK'S/ RINGER'S LACTATE/ NORMAL SALINE TO WHICH 2-3 DROPS OF GENTAMICIN HAVE BEEN ADDED).

Sample volume

EACH BIOPSY SHOULD BE AT LEAST ~5x5 MM (~SIZE OF PENCIL RUBBER/ ERASER) OR LARGER.

Rejection criteria

LABELING ISSUE (UNLABELED/ MISLABELED); MISSING REQUEST FORM; MISMATCH BETWEEN REQUEST FORM & SAMPLE DETAILS; MISSING AGE/ GENDER; WRONG SAMPLE TYPE; INSUFFICIENT SAMPLE; FROZEN SAMPLE.

Other Instructions

IDENTIFY SAMPLES FROM TWINS UNIQUELY WHERE APPLICABLE.

Reference intervals

INTERPRETIVE DATA IS PROVIDED ON THE REPORT.

Clinical Utility

DIAGNOSIS OF PREGNANCY LOSSES ARISING FROM GENOMIC COPY NUMBER VARIATIONS E.G. ANEUPLOIDIES (E.G. TRISOMIES, TURNER SYNDROME, KLINEFELTER SYNDROME), MOSAICISM >20%, MICRODELETIONS & MICRODUPLICATIONS WITHIN THE ASSAY'S RESOLUTION.

Test Limitations/ Confounders

CANNOT DETECT BALANCED CHROMOSOMAL REARRANGEMENTS, SINGLE GENE DISORDERS, MOSAICISM <20% ETC. HIGHER RISK OF UNCERTAIN & INCIDENTAL FINDINGS THAN KARYOTYPING.
05 Jun

CHROMOSOMAL MICROARRAY, PRENATAL, AMNIOTIC FLUID/ CHORIONIC VILLUS SAMPLING (CVS)

vincentochiengde

Category

Molecular genetic pathology & cytogenetics

Sub Category

Cytogenetics

Synonym/Aliases

Prenatal SNP Microarray; Prenatal Array CGH; Array Feto

Abbreviations

ACGH; CMA

Type

Individual Test

Results

RESULTS READY AFTER 18-21 WORKING DAYS

Method

CYTOGENOMIC MICROARRAY (CMA) USING FETAL DNA; CYTOGENOMIC SINGLE NUCLEOTIDE POLYMORPHISM (SNP) MICROARRAY USING FETAL DNA.

Temp

TEMPRATURE BE REFRGIRATED

Setup

BATCHED

Components Parameters

N/A

PRE-ANALYTIC CONSIDERATIONS

Test Ordering Instructions

FILL OUT TEST REQUEST FORM FULLY & LEGIBLY. CLINICAL HISTORY & ULTRASOUND FINDINGS REQUIRED.

Patient preparation

N/A

Sample type

CHORIONIC VILLI (1ST TRIMESTER) OR AMNIOTIC FLUID (2ND TRIMESTER).

Container/ preservative

1ST TRIMESTER: CHORIONIC VILLI IN TISSUE CULTURE MEDIA (OR RPMI/ HANK'S/ RINGER'S LACTATE/ NORMAL SALINE TO WHICH 2-3 DROPS OF GENTAMICIN HAVE BEEN ADDED). 2ND TRIMESTER: 20ML AMNIOTIC FLUID IN STERILE FALCON TUBE. ENSURE PROPER, LEAK PROOF CAPPING.

Sample volume

20ML AMNIOTIC FLUID (IN STERILE CONTAINER; DISCARD FIRST 2ML TO AVOID CONTAMINATION WITH MATERNAL CELLS.) / 20MG CHORIONIC VILLI BIOPSY (IN TISSUE CULTURE MEDIA/ NORMAL SALINE WITH GENTAMICIN DROPS).

Rejection criteria

LABELING ISSUE (UNLABELED/ MISLABELED); MISSING REQUEST FORM; MISMATCH BETWEEN REQUEST FORM & SAMPLE DETAILS; MISSING AGE/ GENDER; WRONG SAMPLE TYPE; INSUFFICIENT SAMPLE; FROZEN SAMPLE.

Other Instructions

DO NOT FREEZE. TIME SENSITIVE THREFORE NOTIFY LAB PRIOR TO COLLECTION & PROMPTLY DELIVER SAMPLE TO THE LAB.

Reference intervals

INTERPRETIVE DATA IS PROVIDED ON THE REPORT.

Clinical Utility

PRENATAL DIAGNOSIS OF GENOMIC COPY NUMBER VARIATIONS E.G. ANEUPLOIDIES (E.G. TRISOMIES, TURNER SYNDROME, KLINEFELTER SYNDROME), MOSAICISM >20%, MICRODELETIONS & MICRODUPLICATIONS WITHIN THE ASSAY'S RESOLUTION.

Test Limitations/ Confounders

CANNOT DETECT BALANCED CHROMOSOMAL REARRANGEMENTS, SINGLE GENE DISORDERS, MOSAICISM <20% ETC. HIGHER RISK OF UNCERTAIN & INCIDENTAL FINDINGS THAN KARYOTYPING.
05 Jun

CHLAMYDIA TRACHOMATIS PCR

vincentochiengde

Category

Molecular genetic pathology & cytogenetics

Sub Category

infectious diseases

Synonym/Aliases

Chlamydophila Trachomatis Pcr; C. Trachomatis Nucleic Acid (Amplification) Test

Abbreviations

C. Trachomatis Pcr; C. Trachomatis Naat; C. Trachomatis Nat.

Type

Individual Test

Results

RESULTS READY AFTER 7 WORKING DAYS

Method

PCR

Temp

AMBIENT OR REFRIGERATED (2-8ºC)

Setup

BATCHED

Components Parameters

N/A

PRE-ANALYTIC CONSIDERATIONS

Test Ordering Instructions

FILL OUT TEST REQUEST FORM FULLY & LEGIBLY. EXACT SAMPLE TYPE MUST BE SPECIFIED.

Patient preparation

N/A

Sample type

VARIABLE I.E. URINE (FIRST MORNING URINE, FIRST CATCH PORTION), EJACULATE, PERITONEAL FLUID, SWAB (E.G. URETHRAL, VAGINAL, RECTAL, ENDOCERVICAL, EYE SWAB), CERVICAL CELLS IN LIQUID BASED CYTOLOGY (LBC) VIAL OR AS PER MANUFACTURER'S INSTRUCTIONS. SELF COLLECTED OR CLINICIAN COLLECTED VAGINAL SWABS ARE ACCEPTABLE IF HANDLED AS PER MANUFACTURER'S INSTRUCTIONS.

Container/ preservative

DRAYON, RAYON OR POLYESTER FIBRE SWABS, PLACED IN VIRAL TRANSPORT MEDIA (VTM) OR OTHER APPROPRIATE MEDIA & WELL CAPPED. FIRST MORNING URINE SHOULD BE COLLECTED IN A STERILE CONTAINER.

Sample volume

>3 ML URINE/ FLUID OR ENTIRE LBC VIAL OR APPROPRIATE SWAB IN TRANSPORT TUBE.

Rejection criteria

LABELING ISSUE (UNLABELED/ MISLABELED); MISSING REQUEST FORM; MISMATCH BETWEEN REQUEST FORM & SAMPLE DETAILS; MISSING AGE/ GENDER; WRONG SAMPLE TYPE (E.G. COTTON SWABS); INSUFFICIENT SAMPLE.

Other Instructions

IF SWAB COLLECTION IS DONE, PLACE SWAB IN TRANSPORT TUBE (WHERE APPLICABLE), BREAK SWAB SHAFT AT THE SCORE LINE & RECAP TUBE WELL.

Reference intervals

NOT DETECTED/ NEGATIVE

Clinical Utility

EVALUATION OF SUSPECTED CHLAMYDIA TRACHOMATIS INFECTION/ SEXUALLY TRANSMITTED INFECTION (STI)/ LYMPHOGRANULOMA VENEREUM (LGV). THIS MAY MANIFEST AS URETHRITIS, CERVICITIS, EPIDIDYMITIS, PROSTATITIS, PELVIC INFLAMMATORY DISEASE, TUBAL FACTOR INFERTILITY ETC. IT MAY ALSO MANIFEST IN NEWBORNS AS EYE DISCHARGE OR ATYPICAL PNEUMONIA.

Test Limitations/ Confounders

- N/A
02 Jun

BRAF V600 MUTATION

vincentochiengde

Category

molecular genetic pathology & cytogenetics

Sub Category

Oncology

Synonym/Aliases

Braf v600

Abbreviations

Braf v600

Type

Individual Test

Results

RESULTS READY AFTER 14 DAYS

Method

PCR-SEQUENCING

Temp

ROOM TEMPERATURE

Setup

SETUP IS PERFORMED DAILY

Components Parameters

N/A

PRE-ANALYTIC CONSIDERATIONS

Test Ordering Instructions

C. TRACHOMATIS PCR; C. TRACHOMATIS NAAT; C. TRACHOMATIS NAT.

Patient preparation

N/A

Sample type

TUMOR POSITIVE FORMALIN-FIXED, PARAFFIN-EMBEDDED (FFPE) BLOCK.

Container/ preservative

FORMALIN FIXED, PARAFFIN EMBEDDED BLOCKS.

Sample volume

SUFFICIENT RESIDUAL TISSUE/ TUMOR MUST BE AVAILABLE ON THE BLOCK

Rejection criteria

LABELING ISSUE (UNLABELED/ MISLABELED); MISSING REQUEST FORM; MISMATCH BETWEEN REQUEST FORM & SAMPLE DETAILS; MISSING AGE/ GENDER; WRONG SAMPLE TYPE; INSUFFICIENT SAMPLE.

Other Instructions

IF TISSUE IS PROVIDED, TISSUE PROCESSING CHARGES WILL BE APPLICABLE

Reference intervals

NEGATIVE/ NOT DETECTED

Clinical Utility

PREDICTION OF ANTI-EGFR TREATMENT RESPONSE FOR METASTATIC COLORECTAL CANCER (MCRC), MELANOMA TUMOR PATIENTS

Test Limitations/ Confounders

PRESENCE OF PCR INHIBITORS IN THE SAMPLE MAY PREVENT DNA AMPLIFICATION. PARADOXICAL RESULTS MAY ARISE DUE TO SELECTION OF INAPPROPRIATE SPECIMEN AND CONTAMINATION DURING SPECIMEN COLLECTION
02 Jun

BCR::ABL, FISH

vincentochiengde

Category

molecular genetic pathology & cytogenetics

Sub Category

cytogenetics

Synonym/Aliases

T(9;22), fish; philadelphia chromosome

Abbreviations

bcr::abl; bcr-abl; bcr/abl; t(9;22); t(9;22)(q34;q11)

Type

Individual Test

Results

Results ready in after 7 working days

Method

fluorescent in situ hybridization (fish)

Temp

Transportation Temprature be refrigirated (2-8ºC)

Setup

Batched

Components Parameters

N/A

PRE-ANALYTIC CONSIDERATIONS

Test Ordering Instructions

Fill out test request form fully & legibly.

Patient preparation

N/A

Sample type

whole blood or bone marrow.

Container/ preservative

sodium heparin (dark green top) vacutainer.

Sample volume

3ml

Rejection criteria

labeling issue (unlabeled/ mislabeled); missing request form; mismatch between request form & sample details; missing age/ gender; wrong sample type; insufficient sample.

Other Instructions

avoid other types of heparin vacutainers e.g. lithium heparin

Reference intervals

Negative / Not Detected

Clinical Utility

detecting, quantifying and monitoring bcr::abl p190, p210 & p230 fusion transcripts. assessing cytogenetic response in patients with chronic myeloid leukemia (cml). detecting philadelphia positive acute lymphoblastic leukemia (all).

Test Limitations/ Confounders

it is less sensitive for detection of bcr::abl fusion transcripts than quantitative pcr in cml patients.
02 Jun

BCR::ABL, QUANTITATIVE PCR

vincentochiengde

Category

molecular genetic pathology & cytogenetics

Sub Category

oncology (hematologic malignancies)

Synonyms/Aliases

bcr::abl, quantitative pcr; philadelphia chromosome

Abbreviations

BCR::ABL; BCR-ABL; BCR/ABL; t(9;22)

Type

Individual Test

Results

Results ready in 3-5 working days

Method

quantitative reverse transcription pcr. positive results for fusion transcripts are quantified as per the international scale (is) & instrument's linearity limit.

Temp

Transportation Temprature be refrigirated (2-8ºC)

Setup

Batched

Components Parameters

N/A; however concurrent CBC/ PBF ordering is required.

PRE-ANALYTIC CONSIDERATIONS

Test Ordering Instructions

Fill out test request form fully & legibly.

Patient preparation

N/A

Sample type

edta whole blood or bone marrow.

Container/ preservative

edta (purple top) vacutainer

Sample volume

3ml

Rejection criteria

labeling issue (unlabeled/ mislabeled); missing request form; mismatch between request form & sample details; missing age/ gender; wrong sample type; insufficient sample.

Other Instructions

N/A

Reference intervals

Negative / Not Detected

Clinical Utility

detecting, quantifying and monitoring p210 abnormal fusion transcripts. assessing molecular response in patients with chronic myeloid leukemia (cml).

Test Limitations/ Confounders

it does not detect p190 (acute lymphoblastic leukemia) and p230 fusion transcripts.
1 … 7 8 9 10
Call us for any questions +254 722 149 505

© GTB Scanlab Nakuru Ltd. Developed by Butterfly Prime Solutions